Aarhus University

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine

Retrieved on: 
Thursday, March 21, 2024
MuSK protein, Exercise, Science Translational Medicine, Charcot–Marie–Tooth disease, NMD, Patient, Brain cell, Human, Myasthenia gravis, Spinal muscular atrophy, Acetylcholine receptor, Facial muscles, QMG, Myasthenia, Safety, Aarhus University, Muscle weakness, Fatigue, Paper, Neuromuscular disease, Pharmaceutical industry

NMD Pharma’s lead development candidate, NMD670, a novel, selective, and orally bioavailable ClC-1 inhibiting small molecule, is used in the preclinical and clinical studies.

Key Points: 
  • NMD Pharma’s lead development candidate, NMD670, a novel, selective, and orally bioavailable ClC-1 inhibiting small molecule, is used in the preclinical and clinical studies.
  • NMD670 is a muscle-targeted therapy which aims to enhance the activation of skeletal muscle fibers and to improve muscle strength and endurance.
  • As a result, patients have impaired skeletal muscle function and often experience severe muscle weakness and fatigue.
  • Access the full paper in Science Translational Medicine online here:
    In October 2022, NMD Pharma announced positive topline data which established the first clinical proof-of-mechanism of NMD Pharma’s novel CIC-1 chloride channel inhibitor approach in patients impacted by MG.

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine

Retrieved on: 
Thursday, March 21, 2024
MuSK protein, Exercise, Science Translational Medicine, Charcot–Marie–Tooth disease, NMD, Patient, Brain cell, Human, Myasthenia gravis, Spinal muscular atrophy, Acetylcholine receptor, Facial muscles, QMG, Myasthenia, Safety, Aarhus University, Muscle weakness, Fatigue, Paper, Neuromuscular disease, Pharmaceutical industry

NMD Pharma’s lead development candidate, NMD670, a novel, selective, and orally bioavailable ClC-1 inhibiting small molecule, is used in the preclinical and clinical studies.

Key Points: 
  • NMD Pharma’s lead development candidate, NMD670, a novel, selective, and orally bioavailable ClC-1 inhibiting small molecule, is used in the preclinical and clinical studies.
  • NMD670 is a muscle-targeted therapy which aims to enhance the activation of skeletal muscle fibers and to improve muscle strength and endurance.
  • As a result, patients have impaired skeletal muscle function and often experience severe muscle weakness and fatigue.
  • Access the full paper in Science Translational Medicine online here:
    In October 2022, NMD Pharma announced positive topline data which established the first clinical proof-of-mechanism of NMD Pharma’s novel CIC-1 chloride channel inhibitor approach in patients impacted by MG.

Emotional Link LLC CEO Naoto Sato Interviews Dr. Morten Christiansen, Cornell University, on "Transformative Solutions for Language Learning Struggles"

Retrieved on: 
Thursday, March 21, 2024
Science, Research, Other Communications, Continuing, Communications, University, Education, Training, Dai, Communication, Privacy, Comprehension, Learning, Business, Cornell University, Cognitive science, Left, Student, Commerce, Psychology, Keio University, Aarhus University, Culture, Language, Multimedia, School

Emotional Link LLC , a business information dissemination company based in Minato Ward, Tokyo, has released an interview article with Professor Morten Christiansen, Cornell University, on "Transformative Solutions for Language Learning Struggles”.

Key Points: 
  • Emotional Link LLC , a business information dissemination company based in Minato Ward, Tokyo, has released an interview article with Professor Morten Christiansen, Cornell University, on "Transformative Solutions for Language Learning Struggles”.
  • View the full release here: https://www.businesswire.com/news/home/20240321778910/en/
    Dr. Morten Christiansen (Left) / Mr. Naoto Sato (Right) (Photo: Business Wire)
    Dr. Christiansen asserts that language fundamentally thrives on collaboration, emphasizing that engaging in interactive communication, akin to the improvisational nature of language games like charades, is highly effective in language learning.
  • Furthermore, Dr. Christiansen emphasizes the significance of learning word combinations as cohesive units, rather than fixating on individual words.
  • Naoto Sato is the CEO of Emotional Link LLC.

Making Long-Term Memories Requires Nerve-Cell Damage

Retrieved on: 
Wednesday, March 27, 2024
Inflammation, Radulović, Psychiatry, Brain, TLR9, COVID, Gene, DNA repair, DSM-IV codes, Cell division, Genome instability, University Medical Center, Infection, Memory, Organelle, Hippocampus, Mouse, DNA, Albert Einstein, Nature, Cancer, Toll-like receptor 9, Neuron, Northwestern University, Doctor of Philosophy, Alzheimer's disease, Genome, Aarhus University, Cytoplasm, Cell, Dominic, B.A, Encephalitis, Ageing, Vaccine

"But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."

Key Points: 
  • "But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."
  • But looking more closely, we found, to our surprise, that TLR9 was activated only in clusters of hippocampal cells that showed DNA damage."
  • But in this population of hippocampal neurons, the DNA damage appeared to be more substantial and sustained.
  • Importantly, the researchers found that blocking the TLR9 inflammatory pathway in hippocampal neurons not only prevented mice from forming long-term memories but also caused profound genomic instability, i.e, a high frequency of DNA damage in these neurons.

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
Thursday, March 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
Thursday, March 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

Job Research Foundation Announces 2024 Grant Recipient

Retrieved on: 
Tuesday, March 12, 2024
Boston Children's Hospital, University of Pennsylvania, Disease, University of Freiburg, Associate, Patient, Hyperimmunoglobulin E syndrome, Research, Gene editing, Rockefeller University, Columbia University, University, Hospital, Aarhus University, Multimedia, University of Newcastle, Barber–Say syndrome, Pharmaceutical industry

NEW YORK, March 12, 2024 /PRNewswire/ -- The Job Research Foundation was established to underwrite research into Job Syndrome, also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), a rare multisystem immunodeficiency disorder.

Key Points: 
  • NEW YORK, March 12, 2024 /PRNewswire/ -- The Job Research Foundation was established to underwrite research into Job Syndrome, also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), a rare multisystem immunodeficiency disorder.
  • This year's recipient, Dr. Rasmus O. Bak, Associate Professor at Aarhus University in Denmark, will receive a grant totaling $200,000.
  • Since 2019 the Job Research Foundation has funded a total of 15 scientific research projects.
  • The Job Research Foundation will start accepting the next round of grant applications in July 2024.

Notice of AGM

Retrieved on: 
Wednesday, March 13, 2024
CSRD, Shareholder, Person, Address, Exercise, Annual report, Climate change, IDS, Chapter Seven, Webcast, ATP, Legislation, Sustainability, Annual general meeting, Chapter Five, Aarhus University, Treasury, Remuneration, Mass meeting, National bank, ID, Central bank, European Central Bank, London Stock Exchange, Trust, Auditor, Corporate sustainability, Euroclear, Climate, Temperature, RNS, EET, Policy, Greenpeace Nordic, Q&A, Annual, Travel, Security (finance)

This notice, which includes the agenda of the Annual General Meeting, the resolution proposals, and the organisational document of the Annual General Meeting, are available on the Company's website at www.nordea.com/agm .

Key Points: 
  • This notice, which includes the agenda of the Annual General Meeting, the resolution proposals, and the organisational document of the Annual General Meeting, are available on the Company's website at www.nordea.com/agm .
  • Before the meeting, questions can be submitted by email to [email protected] or by regular mail to Nordea AGM / Group Legal SATA V5A, Satamaradankatu 5, FI-00020 Nordea, Finland.
  • On the day of this notice to the Annual General Meeting, 21 February 2024, the total number of shares in the Company is 3,521,499,960, which equals 3,521,499,960 votes.
  • This notice is published in English, Swedish and Finnish.

Labroots Hosts 12th Annual Neuroscience Online Event Scheduled on March 6, 2024

Retrieved on: 
Thursday, February 29, 2024
SVKM's NMIMS, Pennsylvania State University, Artificial intelligence, DSM-IV codes, University, Kellogg School, Behavior, Diagnosis, Health, Labroots, Associate, Gubra, Panel discussion, Bangladesh Technical Education Board, Networking hardware, Blood test, Translation, Ethics, NIH, Computer, Data collection, Aarhus University, Associate professor, Initiative, BRAIN, Dementia, Brain, Parkinson's disease, Natural language processing, University of Pennsylvania, Language, Drug discovery, BRAIN Initiative, Neurodegenerative disease, Thought, Social behavior, Heart, Translational neuroscience, Lewy body, Research, Multiple, Neural engineering, Collection, MD, Discovery, Depression, Medical imaging

YORBA LINDA, Calif., Feb. 29, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its free 12th annual event in the Neuroscience Virtual Event Series to be held on March 6, 2024. Marking a decade of sharing ground breaking research and scientific discovery via Labroots' immersive platform, this dynamic event continues its tradition of showcasing some of the brightest minds at the forefront of neuroscience impacting health and disease today.

Key Points: 
  • I am excited to discuss this at Labroots' 12th annual event in the Neuroscience Virtual Event Series."
  • Hosted by Labroots and produced on Chati, participants in the event can connect seamlessly across desktop and mobile devices while engaged in a one-stop educational experience.
  • Remember to use the hashtag #LRneuro to follow the conversation and connect with other members of the global Neuroscience community!
  • Follow @Neuroscience_LR on Twitter and @Neuroscience.LR on Facebook to stay up to date with the latest Trending News in Neuroscience.

Nomination Board's proposals to Nordea's Annual General Meeting 2024 include a new Board member

Retrieved on: 
Monday, February 5, 2024
Nature, Remuneration, Shareholder, National bank, Aarhus University, ATP, Risk, Annual general meeting, AGM, Holding company

The Shareholders' Nomination Board of Nordea Bank Abp announces today its proposals to Nordea's Annual General Meeting (AGM) to be held on 21 March 2024.

Key Points: 
  • The Shareholders' Nomination Board of Nordea Bank Abp announces today its proposals to Nordea's Annual General Meeting (AGM) to be held on 21 March 2024.
  • The proposal of the Shareholders' Nomination Board for the Board of Directors to be elected by the 2024 AGM comprises ten members.
  • Chair of the Shareholders' Nomination Board, Niko Pakalén, says: "I am pleased to present the Nomination Board's proposals to the shareholders.
  • The Shareholders' Nomination Board proposes to the AGM that the following annual remuneration is paid to the members of the Board of Directors elected by the AGM: